Clinical Trials Directory

Trials / Completed

CompletedNCT00210288

Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine

A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
111 (estimated)
Sponsor
Institut Pasteur · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the immune response produced by two doses of SC599 vaccine compared to placebo.

Conditions

Interventions

TypeNameDescription
BIOLOGICALSC599

Timeline

Start date
2005-05-01
Primary completion
2006-09-01
Completion
2007-04-01
First posted
2005-09-21
Last updated
2018-08-08

Locations

2 sites across 2 countries: France, United Kingdom

Source: ClinicalTrials.gov record NCT00210288. Inclusion in this directory is not an endorsement.